All News Epic Corp.

Equities

EPOR

US29428L4032

Market Closed - OTC Markets Other stock markets 07:54:07 19/04/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2022	Sanofi profit gain beats market view on bestseller drug Dupixent	RE
2022	Sanofi to float drug ingredients manufacturing business on May 6	RE

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sanofi profit gain beats market view on bestseller drug Dupixent	28/22/28	RE
Sanofi to float drug ingredients manufacturing business on May 6	01/22/01	RE
Apple, Epic Antitrust Ruling Issued by US Judge: Bloomberg	10/21/10	MT
Apple Inc. : Is it really the end of the Apple supercycle?	22/21/22
Epic Corporation Announces Updates on Disruptive Cryptocurrency	15/19/15	CI
Epic To Seek Acquisitions	15/19/15	CI
Epic Presents the Epic Monetary System	18/19/18	CI
EPIC Corporation Announces the Resignation of James G. Xilas as Officer and Director	04/19/04	CI
Epic Corp. Reports Earnings Results for the Year Ended September 30, 2015	05/16/05	CI
Epic Corp. announced that it expects to receive $2 million in funding.	23/15/23	CI
EPIC Corporation Inc. Introduces AcuFAB (R) Acupressure Insoles	24/14/24	CI
EPIC Corporation Inc. Receives One Time License Fee of $1 Million from Epic's Medicor Corporation	19/14/19	CI
Epic Corp. acquired EPIC Fabric Healthcare Products.	17/14/17	CI
Epic Corporation to Form Joint Venture with Salem Sleep Systems, Inc	13/14/13	CI
Epic Corp. Announces Earnings Results for the Year Ended September 30, 2013	31/13/31	CI
Epic Corp. Reports Earnings Results for the Nine Months Ended June 30, 2013	06/13/06	CI
Lahey Health Signs Agreement with Epic for Better Coordinated Care	28/13/28	CI
Epic Corp. Expands Alternative Healthcare Product Line	20/12/20	CI
Epic Corp. Presents its Sleep Pad on MoneyTV an Internationally-Syndicated Weekly Television Program	11/12/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer